Saunders Finds Life After Allergan on Board at Newly IPO’ed BridgeBio

Source: FiercePharma

Less than 2 months after Allergan was officially taken in by AbbVie, its last helmsman, Brent Saunders, has landed on the board of a young biotech that recently pulled off a large IPO, according to a FiercePharma report.

Saunders has been named an independent director of BridgeBio Pharma, the California biotech said Wednesday. He joins two other new additions to the board: Incyte co-founder and former chairman Randy Scott, and BridgeBio’s own co-founder, economist Andrew Lo.

Read the full article.

Related Content